Breast Cancer | Specialty

Investigators Take Stock of New Landscape for Metastatic HER2-Positive Breast Cancer

November 26th 2020

Breast cancer specialists discuss noteworthy data on efficacy and safety about fam-trastuzumab deruxtecan-nxki, neratinib, and tucatinib.

Dr. Opyrchal on the Current State of Biomarkers in TNBC

November 24th 2020

Mateusz Opyrchal, MD, PhD, discusses the current state of biomarkers in triple-negative breast cancer.

Treatment Selection Becomes Complex Amid Growing Armamentarium in HER2+ Breast Cancer

November 24th 2020

Nusayba Bagegni, MD, discusses prominent data that have emerged in early-stage and metastatic HER2-positive breast cancer.

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

Standardized Frontline CDK4/6 Inhibition Sets the Stage for Further Research in HR+/HER2- Breast Cancer

November 23rd 2020

November 23, 2020 — Katherine K. Clifton, MD, discusses the utility of CDK4/6 inhibitors as frontline treatment for patients with HR-positive/HER2-negative breast cancer, the growing role of PI3K inhibitors in this space, and potential future research directions with these treatments.

Next-Generation Endocrine Therapy Moves Forward in Breast Cancer Trial

November 23rd 2020

November 24, 2020 — Amcenestrant, a new oral form of endocrine therapy that has shown early signs of efficacy, is being evaluated against the current standards of care in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer.

Atezolizumab/Nab-Paclitaxel Induces Clinically Meaningful OS Benefit in PD-L1+ Locally Advanced or Metastatic TNBC

November 20th 2020

The combination of atezolizumab and nab-paclitaxel led to a clinically meaningful overall survival benefit in treatment-naïve patients with locally advanced or metastatic triple-negative breast cancer who had PD-L1 expressing tumor-infiltrating immune cells.

Asian Patients With HR+, HER2- Breast Cancer Have Higher Risk of Recurrence, May Benefit From Additional Adjuvant Abemaciclib

November 20th 2020

November 20, 2020 - Patients from Asian countries with hormone receptor–positive, HER2-negative breast cancer may have a higher risk of disease recurrence than those from non-Asian countries, suggesting that this population may benefit from additional adjuvant treatment with abemaciclib.

Dr. Iwata on Final OS Results From the Phase 3 IMpassion130 Trial in TNBC

November 20th 2020

Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses final overall survival results from the phase 3 IMpassion130 trial in triple-negative breast cancer.

FDA Approves PD-L1 IHC 22C3 pharmDx as Companion Diagnostic for Pembrolizumab in TNBC

November 16th 2020

November 16, 2020 — The FDA has approved the PD-L1 IHC 22C3 pharmDx to aid in the identification of patients with triple-negative breast cancer who are eligible to receive the PD-1 inhibitor pembrolizumab.